Foreign Buying Stabilizes KOSPI Around 2360... KOSDAQ Rises Over 2%, Closes Near 830

Expectations for Early Commercialization of COVID-19 Treatments and Vaccines, Potential Progress in US-China Trade Talks
Reflecting Positive Factors Including Domestic COVID-19 New Cases Staying in the 200s for Two Consecutive Days

[Asia Economy Reporter Oh Ju-yeon] Despite concerns over the resurgence of the novel coronavirus infection (COVID-19), on the 25th, the KOSPI and KOSDAQ indices showed strength, rising by 1% and 2% respectively. Analysts suggest that the easing of US-China tensions and positive news related to COVID-19 treatments and vaccines had a favorable impact on the stock market. It is also notable that foreigners were net buyers in both the KOSPI and KOSDAQ markets on that day.

According to the Korea Exchange on the 25th, the KOSPI closed at 2,366.73, up 1.58% from the previous trading day. Although the KOSPI's rise rate slightly dipped in the morning, it expanded its gains to over 1% after the Central Disease Control Headquarters announced that the number of new COVID-19 cases as of midnight was 280, maintaining the 200s for two consecutive days.

Among the top market capitalization stocks, Samsung Electronics (0.53%), SK Hynix (1.99%), NAVER (1.56%), LG Chem (1.57%), and Hyundai Motor (2.79%) rose, while Samsung Biologics (-0.61%) and Celltrion (-1.13%) declined.

By investor type, individuals sold stocks worth 65.3 billion KRW and institutions sold 123.5 billion KRW, whereas foreigners purchased stocks worth 152.1 billion KRW, driving the index upward.

The KOSDAQ index recorded 836.31, up 2.52% from the previous trading day.

Among the top market capitalization stocks, Celltrion Healthcare (-0.77%), Seegene (-0.37%), and Genexine (-1.87%) declined, while Alteogen (1.74%), Celltrion Pharm (0.36%), and EcoPro BM (0.26%) rose.

Foreign buying continued in the KOSDAQ market as well. Individuals sold stocks worth 134.1 billion KRW, while foreigners and institutions were net buyers of 34.3 billion KRW and 110.1 billion KRW respectively.

Lee Kyung-min, a researcher at Daishin Securities, analyzed, "There is growing expectation for the resumption of an upward trend after a short-term sharp decline," adding, "Various positive factors have emerged, including the development and early commercialization expectations of COVID-19 treatments and vaccines, potential progress in US-China trade negotiations, the US recording 34,567 new COVID-19 cases?the lowest since the end of June?and South Korea maintaining new COVID-19 cases in the 200s for two consecutive days."

This content was produced with the assistance of AI translation services.